본문 바로가기
KERD
논문KCI 등재

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

조현주|오인재|김영철|최유덕|박철규
대한암학회 (Korean Cancer Association)|2021.01|Cancer Research and Treatment|제53권 제1호|pp. 93-103|DOI 10.4143/crt.2020.459

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

EGFR mutationCirculating tumor DNANon–small cell lung carcinomaOsimertinib
주제분류의학일반

초록

Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA. Materials and Methods Patients with activating EGFR mutations in their tumor DNA underwent screening with ctDNA analysis using Mutyper and Cobas v2 assays. Enrolled subjects received osimertinib 80 mg, once daily. Primary endpoint was objective response rate (ORR) and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety. Results Among 39 screened patients, 29 were ctDNA positive for activating EGFR mutations and 19 were enrolled (ex19del, n=11; L858R/L861Q, n=7; G719A, n=1). Median age was 70 and most patients had brain metastases (15/19, 79%). ctDNA test sensitivity for activating EGFR mutations was 74% using both methods and 62% (Mutyper) or 64% (Cobas v2) for individual methods. ORR was 68% (13/19), median PFS was 11.1 months (95% confidence interval [CI], 0.0 to 26.7), and median DoR was 17.6 months (95% CI, 3.5 to 31.7). ORR and median PFS were significantly superior with ex19del (91%; 21.9 months; 95% CI, 5.5 to 38.3) than with L858R/L861Q (43%; 5.1 months; 95% CI, 2.3 to 7.9). One patient discontinued the drug because of drug-related interstitial pneumonitis. Conclusion Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA.

Abstract

Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA. Materials and Methods Patients with activating EGFR mutations in their tumor DNA underwent screening with ctDNA analysis using Mutyper and Cobas v2 assays. Enrolled subjects received osimertinib 80 mg, once daily. Primary endpoint was objective response rate (ORR) and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety. Results Among 39 screened patients, 29 were ctDNA positive for activating EGFR mutations and 19 were enrolled (ex19del, n=11; L858R/L861Q, n=7; G719A, n=1). Median age was 70 and most patients had brain metastases (15/19, 79%). ctDNA test sensitivity for activating EGFR mutations was 74% using both methods and 62% (Mutyper) or 64% (Cobas v2) for individual methods. ORR was 68% (13/19), median PFS was 11.1 months (95% confidence interval [CI], 0.0 to 26.7), and median DoR was 17.6 months (95% CI, 3.5 to 31.7). ORR and median PFS were significantly superior with ex19del (91%; 21.9 months; 95% CI, 5.5 to 38.3) than with L858R/L861Q (43%; 5.1 months; 95% CI, 2.3 to 7.9). One patient discontinued the drug because of drug-related interstitial pneumonitis. Conclusion Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA.

참고문헌 (27)

  1. Cross DA, "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
  2. Janne PA, "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
  3. Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer : AURA study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)
  4. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
  5. Soria JC, "Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
  6. Ramalingam SS, "Osimertinib as first-line treatment of EGFR mutationpositive advanced non-small-cell lung cancer", J Clin Oncol, 36, pp.841~849 (2018)
  7. Ramalingam SS, "Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
  8. Cho BC, "Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC : FLAURA Asian Subset", J Thorac Oncol, 14, pp.99~106 (2019)
  9. Ballard P, "Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity", Clin Cancer Res, 22, pp.5130~5140 (2016)
  10. Reungwetwattana T, "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced nonsmall-cell lung cancer", J Clin Oncol, 36, pp.3290~3297 (2018)
  11. Douillard JY, "Gefitinib treatment in EGFR mutated caucasian NSCLC : circulating-free tumor DNA as a surrogate for determination of EGFR status", J Thorac Oncol, 9, pp.1345~1353 (2014)
  12. Qiu M, "Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer : a meta-analysis", Cancer Epidemiol Biomarkers Prev, 24, pp.206~212 (2015)
  13. Thress KS, "EGFR mutation detection in ctDNA from NSCLC patient plasma : a cross-platform comparison of leading technologies to support the clinical development of AZD9291", Lung Cancer, 90, pp.509~515 (2015)
  14. 박철규, "A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2", Cancer Research and Treatment, 51(2), pp.777~787 (2019), 대한암학회
  15. Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
  16. Gray JE, "Tissue and plasma EGFR mutation analysis in the FLAURA trial : osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer", Clin Cancer Res, 25, pp.6644~6652 (2019)
  17. Molina-Vila MA, "Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial", J Thorac Oncol, 15, pp.416~425 (2020)
  18. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
  19. Weber B, "Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays", BMC Cancer, 14, pp.294~ (2014)
  20. Jenkins S, "Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer", J Thorac Oncol, 12, pp.1061~1070 (2017)
  21. 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회
  22. Sacher AG, "Application of plasma genotyping technologies in non-small cell lung cancer : a practical review", J Thorac Oncol, 12, pp.1344~1356 (2017)
  23. Bhatt VR, "Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer", J Glob Oncol, 3, pp.208~217 (2017)
  24. Sheng M, "Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment : a meta-analysis", Eur J Clin Pharmacol, 72, pp.1~11 (2016)
  25. Yang JC, "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials", Lancet Oncol, 16, pp.141~151 (2015)
  26. 홍민희, "Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer", Yonsei Medical Journal, 60(6), pp.525~534 (2019), 연세대학교의과대학[DOI]
  27. Zhou C, "Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial", J Clin Oncol, 37(15 Suppl), pp.9020~ (2019)

관련 논문AI추천

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2김영철, 박철규, 오인재, 조현주, 최유덕대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion김연주, 이재철, 지원준, 천성민, 최창민대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies강진형, 김동완, 김상위, 안명주, 이종석, 조병철, 한지연, James Chih-Hsin Yang, Tetsuya Mitsudomi대한암학회 · Cancer Research and Treatment2020 · 제52권 제1호Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib TreatmentGee-Chen Chang, Jeng-Sen Tseng, Kang-Yi Su, Kun-Chieh Chen, Kuo-Hsuan Hsu, Sung-Liang Yu, Tsung-Ying Yang, Yen-Hsiang Huang대한암학회 · Cancer Research and Treatment2018 · 제50권 제4호Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer강혜선, 김승준, 김은영, 박동원, 박찬권, 박철규, 양세훈, 여창동, 윤성훈, 이계영, 이민기, 이상훈, 이승룡, 이승현, 이신엽, 이장호, 이재철, 이정은, 임준혁, 장승훈, 장태원, 최창민대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors김상위, 김혜영, 남병호, 민영주, 이건국, 이기형, 이수현, 이영주, 이진수, 정진아, 조은경, 한지연, 한혜선대한암학회 · Cancer Research and Treatment2017 · 제49권 제1호

이 간행물의 다른 논문 (30건)

Practical Advice for South Korean Medical Researchers Regarding Open-Access and Predatory Journals임채홍pp. 1-8TM4SF4 and LRRK2 are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis송지영, 이미숙, 안성빈, 노가원, 성민정, 오두이, 구범모, 송경, 이한나, 최윤라, 장은솔, 김룡남, 정경수, 최준석, 김유진, 신영기pp. 9-24Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients이명아, 최혜진, 변자민, 백선경, 김도연, 김유정, 권정혜, Sam H Ahmedzai, 장근두, 정진영pp. 25-31Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016정규원, 원영주, 박현진, 임지원, 이준아, 박병규, 박미림pp. 32-44Development of a Tongue Immobilization Device Using a 3D Printer for Intensity Modulated Radiation Therapy of Nasopharyngeal Cancer Patients김영비, 박승규, 최유미, 오동렬, 안용찬, 김동현, 주상규, 나초희, 홍채선, 김철종, 권동렬pp. 45-54
원문 보기